Compare ARK Genomic Revolution ETF (ARKG) vs Nuwellis Inc (NUWE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Nuwellis Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Nuwellis Inc trades at $3.18 (market cap $1.10M). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | NUWE | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $558.26 |
52-Week Low | $23.09 | $2.87 |
Market Cap | — | $1.10M |
Enterprise Value | — | -$713.47K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
NUWE trades at $3.04, up 5.56% today, but faces bearish technical signals with oversold RSI readings. The company reported a net loss of $17.52M in 2025 with negative margins, though recent earnings beat expectations in two of the last three quarters. A reverse stock split was executed in June 2026, and new CEO Mike McCormick is focusing on pediatric market expansion.
Outlook remains challenging due to persistent losses and high cash burn, but strategic initiatives in pediatric cardiorenal care and recent FDA engagement offer potential growth. Risks include financial sustainability and competitive pressures. Analyst sentiment is split evenly between Buy and Hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
